XOMA Corporation (XOMAP) P/E Ratio History
UndervaluedTrading at 17.5x vs 5Y avg 25.5x · 50th percentile · Below historical baseline · Data 2020–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, XOMA Corporation (XOMAP) trades at a price-to-earnings ratio of 17.5x, with a stock price of $25.49 and trailing twelve-month earnings per share of $1.94.
The current P/E is 32% below its 5-year average of 25.5x. Over the past five years, XOMAP's P/E has ranged from a low of 12.6x to a high of 89.1x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, XOMAP trades at a 24% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
The PEG ratio of 1.31 (P/E divided by 188% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, XOMAP trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XOMAP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
XOMAP Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
XOMAP P/E vs Peers
Royalty and IP Monetization Vehicles peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $444B | 106.1 | - | -1% | |
| $138B | 17.9 | - | -4% | |
| $317B | 17.6Lowest | 0.83Best | +8%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
XOMAP Historical P/E Data (2020–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $26.27 | $1.65 | 15.9x | -38% |
| FY2025 Q4 | Dec 31 2025 | $26.87 | $1.54 | 17.4x | -32% |
| FY2025 Q3 | - | $26.47 | $2.10 | 12.6x | -51% |
| FY2025 Q1 | Mar 31 2025 | $25.84 | $0.29 | 89.1x | +249% |
| FY2022 Q3 | Sep 30 2022 | $24.32 | $1.66 | 14.7x | -43% |
| FY2022 Q2 | - | $25.40 | $1.62 | 15.7x | -39% |
| FY2022 Q1 | - | $26.34 | $1.82 | 14.5x | -43% |
| FY2021 Q4 | Dec 31 2021 | $26.30 | $1.39 | 18.9x | -26% |
| FY2021 Q3 | - | $26.48 | $0.76 | 34.8x | +36% |
| FY2021 Q2 | Jun 30 2021 | $26.55 | $1.05 | 25.2x | -1% |
| FY2021 Q1 | Mar 31 2021 | $25.00 | $0.94 | 26.5x | +4% |
| FY2020 Q4 | - | $24.99 | $1.17 | 21.3x | -17% |
Average P/E for displayed period: 25.5x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
XOMAP — Frequently Asked Questions
Quick answers to the most common questions about buying XOMAP stock.
What is XOMAP's P/E ratio?
XOMA Corporation (XOMAP) trailing twelve-month P/E ratio is 17.5x, based on TTM diluted EPS of $1.94. The 5-year average P/E is 25.5x and the historical range spans 12.6x to 89.1x.
Is XOMAP stock overvalued or undervalued?
XOMAP trades at 17.5x P/E, below its 5-year average of 25.5x. At the 50th percentile of its historical range (12.6x–89.1x), the stock is priced at a discount to its own history.
Is XOMAP stock expensive?
No, XOMAP is not expensive on a historical basis. The current P/E of 17.5x is below the 5-year average of 25.5x and sits at the 50th percentile of its valuation range.
What is XOMAP's historical P/E range?
Over the past 5 years, XOMAP's P/E ratio has ranged from 12.6x to 89.1x, with a median of 18.9x and an average of 25.5x. The current P/E of 17.5x places the stock at the 50th percentile of this range. Full historical data spans 2020–2026.
How does XOMAP's P/E compare to the S&P 500?
XOMAP trades at 17.5x P/E versus the S&P 500 median of 25.3x. The 31% discount to the market suggests lower growth expectations or perceived higher risk.
How does XOMAP's valuation compare to Healthcare peers?
XOMA Corporation P/E of 17.5x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is XOMAP's PEG ratio?
XOMAP PEG ratio is 1.31, based on a P/E of 17.5x and EPS growth of 188.5%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is XOMAP's earnings yield?
XOMAP earnings yield is 5.73%, the inverse of its 17.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.